Adnexus Therapeutics to Present Data on Adnectin Product Candidate, CT-322, at Gordon Research Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Aug 20, 2007 - Adnexus Therapeutics, Inc. today announced that the company will present data on CT-322, the company's first Adnectin product candidate, at The Gordon Research Conference on Angiogenesis and Microcirculation held in Newport, Rhode Island, August 19-24. The poster to be presented this afternoon by Irvith Carvajal, Senior Scientist, Ph.D. is titled "CT-322: A novel specific VEGFR-2-blocking protein therapeutic agent that inhibits tumor growth in preclinical studies."CT-322 is an Adnectin that was designed to be both a potent and highly specific antagonist of the vascular endothelial growth factor receptor 2 (VEGFR-2). VEGFR-2 activation is believed to be the primary driver of the growth of new blood vessels that support tumor growth. CT-322 has been demonstrated in preclinical studies to block activation of VEGFR-2 by all of its known protein activators, VEGF-A, VEGF-C, and VEGF-D.
In various preclinical animal models, CT-322 was shown to inhibit tumor growth and also reduce metastases. In addition, CT-322 decreased the density of tumor microvessels and remodeled tumor vasculature compared to control animals. Treatment with CT-322 also modulated three different biomarkers as would be predicted for an active antiangiogenic agent.
CT-322 is currently in Phase 1 clinical development in oncology in the United States, and in February 2007 Adnexus announced interim results of an ongoing Phase 1 open-label, dose-escalation study in patients with advanced cancers.
Adnectins are a novel, proprietary class of targeted biologics that are derived from a well-characterized protein, fibronectin, that is prevalent throughout the human body. Adnexus is the exclusive developer of Adnectins.
About Adnexus Therapeutics
Adnexus Therapeutics is focused on generating vital medicines through the discovery, development, and commercialization of a new class of drugs, Adnectins. Adnexus' first product candidate, Angiocept (CT-322), is in Phase 1 clinical development in oncology in the United States. The company also has a pipeline of other Adnectin products in preclinical research across multiple therapeutic areas. Adnectins are designed and optimized using PROfusion, the company's patented protein design engine that enables rapid optimization of protein therapeutics. The company is funded by five leading venture capital firms: Atlas Venture, Flagship Ventures, Polaris Venture Partners, Venrock, and HBM BioVentures.
Adnectin(TM), Adnexus(TM) Therapeutics and PROfusion(TM) are trademarks of Adnexus(TM) Therapeutics, Inc. Adnexus(SM) Therapeutics is a service mark of Adnexus(TM) Therapeutics.
Contact
Adnexus Therapeutics, Inc.
Katrine Bosley, 781-891-3745
Vice President Business Development
pr@adnexustx.com
or
Media:
Suda Communications
Paul Kidwell, 617-296-3854
paulkidwell@comcast.net
Clinical Trial Results Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Dec
